We have addressed this difficulty by using a unique liposome-based delivery system with an EGFR targeting peptide displayed at the surface of the lipopolyplex, achieving for the first time tumour cell-specific uptake and expression of the EGFR biosensor in vivo. Here, EGFR is linked to neoplasm.